{"id":564644,"date":"2021-09-20T22:58:01","date_gmt":"2021-09-20T22:58:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=564644"},"modified":"2021-09-20T22:58:01","modified_gmt":"2021-09-20T22:58:01","slug":"spinal-muscular-atrophy-treatment-market-to-witness-growth-by-2030-key-companies-includes-novartis-cytokinetics-astellas-biogen-novartis-roche-ptc-therapeutics-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/spinal-muscular-atrophy-treatment-market-to-witness-growth-by-2030-key-companies-includes-novartis-cytokinetics-astellas-biogen-novartis-roche-ptc-therapeutics-and-others_564644.html","title":{"rendered":"Spinal Muscular Atrophy Treatment Market to Witness Growth by 2030 | Key Companies includes – Novartis, Cytokinetics, Astellas, Biogen, Novartis, Roche, PTC Therapeutics and Others"},"content":{"rendered":"
\n
\"Spinal<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Spinal Muscular Atrophy Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Spinal Muscular Atrophy Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

The Spinal Muscular Atrophy market report<\/strong> covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice\/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Spinal<\/p>\n

Spinal Muscular Atrophy: An Overview<\/strong><\/p>\n

According to the National Institute of Health (NIH), Spinal muscular atrophy is a genetic disorder characterized by weakness and wasting (atrophy) in muscles used for movement (skeletal muscles). It is caused by a loss of specialized nerve cells, called motor neurons that control muscle movement. The weakness tends to be more severe in the muscles that are close to the center of the body (proximal) compared to muscles away from the body’s center (distal). The muscle weakness usually worsens with age.<\/p>\n

SMA is a motor neuron disease caused by Bi-allelic mutation of survival motor neuron gene 1 (SMN1). There are two identical genes SMN1 (telomeric copy) and SMN2 (centromeric copy) present at human chromosome 5q13. These genes are responsible to synthesize survival motor neuron protein which is necessary for the normal function of motor neurons that control our muscles. The insufficient production of SMN proteins leads to debilitating and often fatal muscle weakness.<\/p>\n

Spinal Muscular Atrophy Market Key Facts<\/strong><\/p>\n